Skip to content

Study · Randomized controlled trial · n = 155 · 2023

4 results

Gender differences in weight gain during attempted and successful smoking cessation on dulaglutide treatment: a predefined secondary analysis of a randomised trial.

Baur F, Atila C, Lengsfeld S, Burkard T, Meienberg A, Bathelt C, Christ-Crain M, Winzeler B

BMJ nutrition, prevention & health19 Dec 2023Cited by 3 (Europe PMC)

PMID38264360 (opens in a new tab)PMCIDPMC10800263 (opens in a new tab)DOI10.1136/bmjnph-2023-000781 (opens in a new tab)PepBankPUB-38264360
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women attempting smoking cessation, substantial weight gain was less frequent with dulaglutide than placebo.

    In plain wordsIn women trying to stop smoking, substantial weight gain was less common with dulaglutide than placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseSubstantial weight gain in women
    Study

    n = 155

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 mg weekly · 12 weeksAs given in this study (human).

    Measurements

    Substantial weight gain
    1%
    dulaglutide women
    Substantial weight gain
    24%
    placebo women

    Source sentences

    Summary
    Female patients were less likely to have substantial weight gain on dulaglutide compared with placebo (1% (n=1/83) vs 24% (n=17/72); p<0.001), while this dulaglutide effect was less pronounced in males (0% (n=0/44) vs 5% (n=3/56); p=0.333).
    2 context sentences
    Summary · context
    Predefined secondary analysis of a placebo-controlled, double-blind, parallel-group, superiority randomised trial including 255 adults who smoke daily (155 women, 100 men).
    Summary · context
    Participants received weekly dulaglutide (1.5 mg) or placebo (0.9% sodium chloride) in addition to standardised smoking cessation care (varenicline 2 mg/day plus behavioural counselling) over 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In men attempting smoking cessation, substantial weight gain occurred in 0% with dulaglutide versus 5% with placebo, without statistical significance.

    In plain wordsIn men trying to stop smoking, substantial weight gain did not differ significantly between dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSubstantial weight gain in men
    Study

    n = 100

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 mg weekly · 12 weeksAs given in this study (human).

    Measurements

    Substantial weight gain
    0%
    dulaglutide men
    Substantial weight gain
    5%
    placebo men

    Source sentences

    Summary
    Female patients were less likely to have substantial weight gain on dulaglutide compared with placebo (1% (n=1/83) vs 24% (n=17/72); p<0.001), while this dulaglutide effect was less pronounced in males (0% (n=0/44) vs 5% (n=3/56); p=0.333).
    2 context sentences
    Summary · context
    Predefined secondary analysis of a placebo-controlled, double-blind, parallel-group, superiority randomised trial including 255 adults who smoke daily (155 women, 100 men).
    Summary · context
    Participants received weekly dulaglutide (1.5 mg) or placebo (0.9% sodium chloride) in addition to standardised smoking cessation care (varenicline 2 mg/day plus behavioural counselling) over 12 weeks.

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    Among adults attempting smoking cessation on dulaglutide, absolute weight change did not differ between women and men.

    In plain wordsIn people trying to stop smoking with dulaglutide, weight change did not differ between women and men.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeAbsolute weight change by gender
    Study

    n: not reported in source

    Comparator
    Men receiving dulaglutide
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    No gender differences were observed in absolute or relative weight change neither on dulaglutide nor placebo treatment.
    2 context sentences
    Summary · context
    Predefined secondary analysis of a placebo-controlled, double-blind, parallel-group, superiority randomised trial including 255 adults who smoke daily (155 women, 100 men).
    Summary · context
    Participants received weekly dulaglutide (1.5 mg) or placebo (0.9% sodium chloride) in addition to standardised smoking cessation care (varenicline 2 mg/day plus behavioural counselling) over 12 weeks.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    Among adults attempting smoking cessation on dulaglutide, relative weight change did not differ between women and men.

    In plain wordsIn people trying to stop smoking with dulaglutide, percentage weight change did not differ between women and men.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeRelative weight change by gender
    Study

    n: not reported in source

    Comparator
    Men receiving dulaglutide
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    No gender differences were observed in absolute or relative weight change neither on dulaglutide nor placebo treatment.
    2 context sentences
    Summary · context
    Predefined secondary analysis of a placebo-controlled, double-blind, parallel-group, superiority randomised trial including 255 adults who smoke daily (155 women, 100 men).
    Summary · context
    Participants received weekly dulaglutide (1.5 mg) or placebo (0.9% sodium chloride) in addition to standardised smoking cessation care (varenicline 2 mg/day plus behavioural counselling) over 12 weeks.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT03204396

Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues

University Hospital, Basel, Switzerlandn = 25626 Jun 2017 to 30 Aug 2022

Glucagon-like Peptide-1 · Smoking Cessation · Weight Change, Body · Craving

Trial pageClinicalTrials.govUpdated 13 Sept 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.